Form 4: ANI Pharmaceuticals Executive Reports Future Stock Sale Under Pre-Arranged Trading Plan
Insider Transaction Report
Meredith Cook, SR. VP, General Counsel & Secretary of ANI Pharmaceuticals Inc., reported the future sale of 400 shares of common stock on July 14, 2025, executed under a pre-established Rule 10b5-1 trading plan.
Summary
- Meredith Cook, SR. VP, General Counsel & Secretary of ANI Pharmaceuticals Inc. (ANIP), reported a transaction involving the company's common stock.
- On July 14, 2025, Cook disposed of 400 shares of ANIP common stock.
- The shares were sold at a price of $64.88 per share.
- Following this transaction, Cook beneficially owns 78,945 shares of common stock.
- The sale was conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by the reporting person on September 17, 2024.
Sentiment
Score: 5
Explanation: The transaction is a routine insider sale executed under a pre-arranged Rule 10b5-1 trading plan, which is a common practice for executives for personal financial planning and does not typically signal a change in company outlook or performance.
Positives
- No direct positives related to company performance or operational improvements are indicated by this routine insider transaction.
Negatives
- No direct negatives related to company performance or significant insider selling signal are indicated, as the sale is part of a pre-arranged plan.
Risks
- NA
Future Outlook
This Form 4 filing is a report of a specific insider transaction and does not contain any forward-looking statements or guidance regarding the company's future outlook.
Management Comments
- Meredith Cook executed a sale of 400 shares of common stock pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on September 17, 2024.
Industry Context
This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide specific industry context beyond the company's general operations within the pharmaceutical sector. Such transactions are common across all industries for executive financial planning.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| NA | NA | NA | NA | NA |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| NA | NA | NA | NA |
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: This is a routine insider transaction under a pre-arranged plan, generally not indicative of significant company-specific news or a change in management's confidence in the company's prospects.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| September 17, 2024 | Date the Rule 10b5-1 trading plan was adopted by Meredith Cook. |
| July 14, 2025 | Date of the reported transaction (sale of 400 shares of common stock). |
Recommendation
holdKeywords
ANI Pharmaceuticals, ANIP, Form 4, insider transaction, stock sale, Meredith Cook, Rule 10b5-1 plan, common stock, corporate governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.